Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Jacot W, Heudel PE, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Courtinard C, Cottu P, Robain M, Mailliez A. Jacot W, et al. Int J Cancer. 2019 Dec 15;145(12):3359-3369. doi: 10.1002/ijc.32402. Epub 2019 Jun 20. Int J Cancer. 2019. PMID: 31087564
[Node negative breast cancer. Beyond international consensus: a pragmatic approach].
Penault-Llorca F, Coeffic D, Delozier T, Dohollou N, Freyer G, Gligorov J, Hardy-Bessard AC, Jacot W, Misset JL, Nabholtz JM, Petit T, Spielmann M, Namer M. Penault-Llorca F, et al. Among authors: jacot w. Bull Cancer. 2011 Jul;98(7):807-25. doi: 10.1684/bdc.2011.1395. Bull Cancer. 2011. PMID: 21727059 French.
[Neoadjuvant treatment of breast cancer: implications for the pathologist].
Le Guellec S, Perallon R, Alunni JP, Charitansky H, Leaha C, Gonzalez AM, Chateau MC, Simony-Lafontaine J, Jacot W, Gutowski M, Penault-Llorca F, Dalenc F, Lacroix-Triki M. Le Guellec S, et al. Among authors: jacot w. Ann Pathol. 2011 Dec;31(6):442-54. doi: 10.1016/j.annpat.2011.10.003. Epub 2011 Nov 23. Ann Pathol. 2011. PMID: 22172117 Review. French.
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, de Boer RH, Jacot W, McGreivy J, Suzuki S, Zhu M, McCaffery I, Loh E, Gansert JL, Kaufman PA. Robertson JF, et al. Among authors: jacot w. Lancet Oncol. 2013 Mar;14(3):228-35. doi: 10.1016/S1470-2045(13)70026-3. Epub 2013 Feb 13. Lancet Oncol. 2013. PMID: 23414585 Clinical Trial.
230 results